Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 13, 2002

Primary Completion Date

September 13, 2013

Study Completion Date

August 22, 2026

Conditions

Adult Solid Neoplasm

Interventions

DRUG

Erlotinib Hydrochloride

Given orally

DRUG

Irinotecan Hydrochloride

Given IV

Trial Locations (1)

Mayo Clinic in Rochester, Rochester

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH